ScripChina’s cell therapy market will grow into an exclusive space for domestic companies, at least over the coming years, after Gilead Sciences, Inc. on 13 September divested through Kite Pharma, Inc.
ScripOn 12 July, Legend Biotech Corp. , a successful China and US-based cell therapy developer, was reported to have received a buyout offer and retained investment bankers at Centerview Partners to help
In VivoDigital health decision makers recently gathered in Los Angeles, CA, at ViVE 2024 to share ideas for governance and regulation of artificial intelligence tools, like large language models. While their
Pink SheetConsumer data protection is obviously high on the minds of regulators in China, as the country's first-ever Personal Information Protection Law (PIPL) takes effect from November. Already, another sepa